Are patient education and self-care advantageous for patients with head and neck cancer? A feasibility study

Anne Söderlund Schaller | Elena Dragiòti | Gunilla M. Liedberg | Britt Larsson

1Pain and Rehabilitation Centre and Department of Medical and Health Sciences, Linköping University, Linköping, Sweden
2Division of Occupational Therapy, Department of Social and Welfare Studies, Faculty of Health Sciences, Campus Norrköping, Linköping University, Linköping, Sweden

Correspondence
Anne Söderlund Schaller, Rehabilitation Medicine, Department of Medicine and Health Sciences (IMH), University of Linköping, Linköping SE-581 85, Sweden. Email: anne.schaller@liu.se

1 INTRODUCTION

1.1 Background and objectives

Pain prevalence in patients with head and neck cancer (HNC) is 50%–80% and related to tumour, surgery, chemotherapy and radiotherapy treatment (RT) (van der Molen et al., 2009). Poor pain management can be due to inadequate pain assessment and lack of knowledge among caregivers as well as among patients with cancer (Oldenmenger, Sillevis Smitt, van Dooren, Stoter, & van der Rijt, 2009). For example, despite severe pain, patients with cancer only used about half their prescribed medication (Miaskowski et al., 2001) and patients’ beliefs such as fear of addiction, misunderstanding about dosages and feelings that it is not possible to treat the pain adequately can provide barriers to optimal management of cancer pain (Gunnarsdottir, Donovan, Serlin, Voge, & Ward, 2002; Ward et al., 1993). Systematic reviews conclude a decrease in pain intensity for patients with cancer is associated with education about pain (Bennett, Bagnall, & Jose Closs, 2009; Howell, Harth, Brown, Bennett, & Boyko, 2017; Jho, Myung, Chang, Kim, & Ko, 2013; Koller, Miaskowski, De Geest, Opitz, & Spichiger, 2012; Ling, Lui, & So, 2012; Marie, Luckett, Davidson, Lovell, & Lal, 2013). One systematic review concludes positive effects of education for patients with cancer on depression, anxiety and quality of life (QoL) (Howell et al., 2017). However, one review found no effect of patient education on QoL in patients with cancer (Ling et al., 2012). Educational interventions for sleep disturbance are sparse (Langford, Lee, & Miaskowski, 2012). Self-care (SC) refers to what patients do on their own to achieve, maintain and promote optimal health (Denyes, Orem, Bekel, & SozWiss, 2001) and may decrease pain in several pain conditions (Du et al., 2011; Oliveira et al., 2012). Pain in patients with HNC has been reported to be difficult to treat with analgesics (Epstein et al., 2002).
The effect of education and SC on pain and other common symptoms in patients with HNC needs to be elucidated. This study evaluated whether patient education and individually tailored SC reduces pain intensity and improves QoL, mood and sleep during and after RT treatment.

We hypothesized that individually tailored patient education and adapted SC can help reduce pain, maintain QoL, stabilize mood and improve sleep in patients with HNC during and after RT.

## METHODS

### Trial design

This two-armed feasibility study compared patient education on management of cancer pain in combination with advice on SC. This trial is registered in ClinicalTrials.gov Identification NCT03089736.

### Participants

The participants were patients with HNC undergoing RT and referred to the Pain and Rehabilitation Centre (PRC) (University Hospital, Linköping, Sweden) for anticipated pain. It was not possible to include patients in the present study before the start of RT. The Swedish law restricts contact to patients before enrolment to the PRC. The patients were included within 2 weeks after receiving ongoing RT. The following inclusion criteria were used as follows: able to read, write and understand Swedish, registered in RT with curative intent and 18 years of age or older. In connection with scheduled RT, verbal and written information about the study was provided to all available patients by trained research nurses (TRN). After 1 week, the eligible patients were asked whether they wanted to be included in the study. Data in this study were collected as short message services (SMS) and at the PRC.

### Interventions

#### Both groups

All participants answered a SMS with seven items on pain intensity and interference every Monday, Wednesday and Friday during the 10-study weeks. If the SMS survey showed ≥3 numeric rating scales step increase on any items, a TRN phoned the patient the same day (no later than 3 days if a weekend). Based on the SMS scores, pharmacological treatment was promptly prescribed or adjusted. If the patient was displeased with the pain relief at the next day's phone contact with a TRN (or at next scheduled individual weekly follow-up if imminent), the pharmacological treatment was adjusted. Both groups were offered care as usual at the PRC. Thus, they were encouraged to contact the TRNs by phone and had access to advice from the TRNs. The pharmacological treatment was based on identical principles for both groups and prescribed by the physicians according to the ward's policies (Appendix S1).

#### The intervention group

The scientific literature (Koller et al., 2012; Lovell et al., 2014) on patient education on management of cancer pain was scrutinized. Six essential education areas were identified: pain and pain physiology, pain medication, side effects of medication and prevention of side effects, abuse of medications and advice on sleep and anxiety. To make it possible to tailor education interventions for each patient, a procedure to match The Barriers Questionnaire II (BQ-II) items to the six educational areas was undertaken. Thus, the BQ-II scoring of the items (several items could be assigned the same education area) coordinated by most of a group of nurses (10 experienced nurses employed at PRC and the first author [AS]) to each education area (Table 1) constituted the base for the individual tailoring of education. The inter-rater reliability of the item-to-education coordination process was measured using a two-way mixed, consistency, average-measures intraclass correlation (ICC) to assess the degree that the 11 coders provided consistency in their ratings of education areas across the 27 items of the BQ-II. The ICC was .91. A minimum summed BQ-II score (Table 1) of the group of items assigned to each education area decided whether and which education should be delivered.

At week 1 (baseline [BL]), a TRN delivered a PowerPoint presentation covering the education areas. This presentation was labelled education session 1 (ES 1). To ensure that as many current needs as possible were addressed at week 4 (ES 2), the TRN initiated a structural discussion with the patient on the specific education areas presented at ES 1. If needed, based on the second scoring of BQ-II 1 week before the ES 2, additional education areas were presented at ES 2.

**Individually tailored self-care**

The scientific literature of SC for patients with cancer was reviewed (Johnston et al., 2009; Wong et al., 2006; Worthington et al., 2011), which was supplemented with the first authors and six nurses employed at PRC clinical experiences of pain care regarding patients with HNC. Fourteen SC measures were identified that covered maintaining well-being, prevention of symptoms and pain relief of mouth and throat (Appendix S2). At weekly follow-ups at the PRC, adjustments or initiations of SC were suggested depending on the previous three SMS scores. As the intention was a preventive approach, SC measurement was systematically selected and suggested (Table 2) if the score on any of the SMS items was ≥3 (except ≥1 on the item pain interferences on general activities). In addition, the TRN verbally presented and provided structured and detailed written information on the recommended SC (Appendix S2).

#### The control group

The control group did not receive the individual tailored education sessions and the systematic adjustments of SC at weekly follow-up.
However, the weekly follow-up of the control group was consistent with the usual care at the PRC. That is, if the patient asked for advice or if it was apparent to a TRN that one or more unstructured SCs would be beneficial, verbal advice regarding SC that the TRN came to think of was provided. This was necessary for ethical reasons.

2.4 | Outcomes

2.4.1 | Primary outcomes

Pain intensity and pain interference

The primary outcome measurements included seven items about pain intensity and pain interference the previous 24 hr reported by both groups of patients and collected by SMS every Monday, Wednesday and Friday during the 10-study weeks.

The University of California San Francisco (UCSF) Oral Cancer Pain Questionnaire (Connelly & Schmidt, 2004) measures pain experiences from the oral cavity and consists of eight items scored on a scale from 0 (no pain)–10 (the most intense pain). In the SMS survey, two items from the Oral Cancer Pain Questionnaire were added on pain intensity in connection with and without speaking, talking and drinking. The Oral Cancer Pain Questionnaire is valid for patients with oral cancer pain (Connelly & Schmidt, 2004; Kolokythas, Connelly, & Schmidt, 2007).

The Brief Pain Inventory (BPI) measures two targets: the subjective intensity of pain and how pain interferes with daily activities (Cleeland & Ryan, 1994). The BPI consists of 12 items: five items related to pain intensity and seven items related to pain interference on function both rated on a 0 (no interference)–10 (interferes completely) scale. In the SMS survey, five items on pain interference
from the BPI were included general activities, mood, relations, sleep and enjoyment of life. The BPI instrument has been validated for patients with cancer (Cleeland & Ryan, 1994; Kumar, 2011). For each subscale and item, the average score of the three weekly scores was calculated.

2.4.2 Secondary outcomes

A survey questionnaire including seven validated patient-reported outcome measurements was used to collect the outcomes. Answered at BL, at 4 weeks and at 10 weeks, the secondary outcomes cover QoL, pain intensity, pain interference, psychological aspects and barriers towards pain management. A part of the secondary outcomes BL data are reported elsewhere (Schaller, Dragioti, Liedberg, & Larsson, 2017).

| Items on pain three times weekly by SMS | Self-care instruction recommended* |
|----------------------------------------|-----------------------------------|
| Pain intensity                          |                                   |
| When talking, eating and drinking       | 3–4, 9–11                         |
| When not talking, eating or drinking    | 3–4, 9–11                         |
| Pain interference                       |                                   |
| General activities                      | 1–4                               |
| Mood                                   | 1–2, 8                            |
| Relations with other people             | 8                                 |
| Sleep                                  | 5–7                               |
| Enjoyment of life                      | 1–2, 8                            |

*Number of self-care refers to numbers in Appendix S2.

The Euro QoL-5 Dimension Questionnaire (EQ-5D) assesses health outcome and perceived state of health (Brooks, 1996). The questionnaire comprises five items: mobility, self-care, usual activities, pain and discomfort, anxiety and depression. Each item has three response scales – no problems, some problems and extreme problems – and the answers were coded 1–3. An algorithm developed for EQ-5D was used to calculate the final individual score. The EQ-5D score has a range from −0.5–1, where negative values mean low QoL and 1 means no reduction in QoL. The EQ-5D scores were determined by applying scores from standard population values (Dolan, 1997). The second part of the EQ-5D is the Euro Quality of Life Vertical Visual Analogue Scale (EQ-VAS), which measures the respondent’s general health on a vertical visual analogue line with 100-scale steps with the endpoints labelled “Best imaginable health state” and “Worst imaginable health state” (Fayers & Machin, 2013).

The EQ-5D, a valid and reliable instrument (Coons, Rao, Keininger, & Hays, 2000), was selected because it is a generic instrument that can be used for patients with different conditions and diseases (Fayers & Machin, 2013).

Pain intensity and pain interference

The Brief Pain Inventory (BPI) measures intensity of pain and pain interference (see description above) (Cleeland & Ryan, 1994). The scores were summed, and mean values of the items of pain interference and pain intensity items were calculated. The Swedish version of BPI used in this study has been linguistically validated (Anderson, 2019) but has not yet been psychometrically validated.

Anxiety and depression

The Hospital Anxiety and Depression Scale (HADS) assesses anxiety and depression (Bjelland, Dahl, Haug, & Neckelmann, 2002). This scale consists of 14 items: seven items are related to anxiety...

### Table 3: Participant characteristics at baseline

| Characteristic                  | Total (N = 64) | Intervention group (N = 34) | Control group (N = 30) | p-valuea |
|---------------------------------|----------------|-----------------------------|------------------------|----------|
| Age (years) (M, SD)             | 65.05 (±10.47) | 64.0 (±10.42)               | 66.3 (±10.57)          | .38      |
| Women                           | 25 (39.1)      | 12 (35.3)                   | 13 (43.3)              | .51      |
| Living situation                |                |                             |                        |          |
| Not living alone                | 42 (65.6)      | 22 (64.7)                   | 20 (66.7)              | .86      |
| Living alone                    | 22 (34.4)      | 12 (35.3)                   | 10 (33.3)              |          |
| Education                       |                |                             |                        |          |
| Primary                         | 10 (15.6)      | 4 (11.8)                    | 6 (20.0)               | .25      |
| Second upper school/vocational  | 28 (43.8)      | 13 (38.2)                   | 15 (50.0)              |          |
| College/University              | 26 (40.6)      | 17 (50.0)                   | 9 (30.0)               |          |
| Smoking habits                  |                |                             |                        |          |
| Non-smokers                     | 26 (40.6)      | 15 (44.1)                   | 11 (36.7)              | .83      |
| Smokers                         | 10 (15.6)      | 5 (14.7)                    | 5 (16.7)               |          |
| Ex-smokers                      | 28 (43.8)      | 14 (41.2)                   | 14 (46.7)              |          |

Abbreviations: M, mean; SD, Standard deviation.

aStudent t test for continuous variables or chi-square test for categorical variables.
| Variables                        | Intervention group (N = 34) | Control group (N = 30) | Regression coefficients (95% CI) | B   | p-value |
|---------------------------------|----------------------------|------------------------|---------------------------------|-----|---------|
| **Pain intensity Q1 (0–10)**    |                            |                        |                                 |     |         |
| Overall effect: p = 0.50        |                            |                        |                                 |     |         |
| 1 week (baseline)               | 1.94 (2.09)                | 1.80 (2.22)            | -                               | -   | -       |
| 2 weeks                         | 2.11 (1.46)                | 2.62 (2.31)            | 0.82 (0.36 to 1.28)             | .001|         |
| 3 weeks                         | 2.90 (1.72)                | 3.63 (2.59)            | 1.83 (1.11 to 2.56)             |     | .000    |
| 4 weeks                         | 3.00 (1.77)                | 3.74 (2.71)            | 1.99 (1.13 to 2.84)             |     | .000    |
| 5 weeks                         | 3.13 (1.62)                | 3.72 (2.80)            | 1.94 (0.98 to 2.89)             |     | .000    |
| 6 weeks                         | 3.28 (1.90)                | 3.73 (2.76)            | 1.90 (0.95 to 2.84)             |     | .000    |
| 7 weeks                         | 2.70 (1.95)                | 3.34 (2.37)            | 1.38 (0.35 to 2.40)             |     | .009    |
| 8 weeks                         | 2.21 (1.76)                | 2.64 (2.61)            | 0.71 (0.48 to 1.90)             |     | .240    |
| 9 weeks                         | 2.04 (1.68)                | 2.04 (2.26)            | 0.34 (0.74 to 1.44)             |     | .530    |
| 10 weeks                        | 2.23 (1.86)                | 1.83 (2.03)            | -0.19 (-1.32 to 0.95)           |     | .743    |
| **Pain intensity Q2 (0–10)**    |                            |                        |                                 |     |         |
| Overall effect: p = 0.36        |                            |                        |                                 |     |         |
| 1 week (baseline)               | 1.30 (1.45)                | 1.33 (1.93)            | -                               | -   | -       |
| 2 weeks                         | 1.52 (1.26)                | 1.93 (1.94)            | 0.60 (0.25 to 0.95)             | .001|         |
| 3 weeks                         | 2.17 (1.41)                | 2.95 (2.49)            | 1.62 (1.06 to 2.19)             |     | .000    |
| 4 weeks                         | 2.32 (1.56)                | 3.12 (2.51)            | 1.87 (1.18 to 2.57)             |     | .000    |
| 5 weeks                         | 2.39 (1.56)                | 3.02 (2.56)            | 1.77 (1.02 to 2.52)             |     | .000    |
| 6 weeks                         | 2.61 (1.74)                | 2.96 (2.63)            | 1.71 (0.93 to 2.48)             |     | .000    |
| 7 weeks                         | 2.14 (1.81)                | 2.67 (2.33)            | 1.25 (0.36 to 2.14)             |     | .006    |
| 8 weeks                         | 1.88 (1.65)                | 2.10 (2.28)            | 0.84 (0.13 to 1.80)             |     | .090    |
| 9 weeks                         | 1.62 (1.52)                | 1.57 (1.98)            | 0.44 (0.46 to 1.35)             |     | .338    |
| 10 weeks                        | 1.74 (1.54)                | 1.46 (1.67)            | -0.008 (-0.95 to 0.93)          |     | .987    |
| **Pain interference Q1 (0–10)**|                            |                        |                                 |     |         |
| Overall effect: p = 0.83        |                            |                        |                                 |     |         |
| 1 week (baseline)               | 1.29 (1.41)                | 1.21 (1.98)            | -                               | -   | -       |
| 2 weeks                         | 1.56 (1.44)                | 1.64 (2.03)            | 0.43 (-0.19 to 1.05)            | .176|         |
| 3 weeks                         | 2.10 (1.78)                | 2.26 (2.56)            | 1.05 (0.24 to 1.86)             |     | .011    |
| 4 weeks                         | 2.44 (1.83)                | 2.57 (2.99)            | 1.42 (0.43 to 2.41)             |     | .005    |
| 5 weeks                         | 2.60 (2.05)                | 2.87 (3.05)            | 1.73 (0.92 to 2.53)             |     | .000    |
| 6 weeks                         | 2.67 (2.12)                | 2.52 (2.61)            | 1.34 (0.50 to 2.18)             |     | .002    |
| 7 weeks                         | 2.70 (2.46)                | 2.55 (2.55)            | 1.26 (0.39 to 2.12)             |     | .004    |
| 8 weeks                         | 2.28 (2.19)                | 2.07 (2.38)            | 0.93 (-0.01 to 1.87)            |     | .052    |
| 9 weeks                         | 2.13 (2.14)                | 1.51 (2.13)            | 0.48 (-0.42 to 1.38)            |     | .297    |
| 10 weeks                        | 2.19 (2.06)                | 1.27 (1.78)            | 0.03 (-0.79 to 0.84)            |     | .948    |
| **Pain interference Q2 (0–10)**|                            |                        |                                 |     |         |
| Overall effect: p = 0.73        |                            |                        |                                 |     |         |
| 1 week (baseline)               | 1.28 (1.31)                | 1.29 (1.82)            | -                               | -   | -       |
| 2 weeks                         | 1.53 (1.44)                | 1.72 (2.08)            | 0.43 (0.16 to 0.70)             | .002|         |
| 3 weeks                         | 2.04 (1.73)                | 2.31 (2.36)            | 1.02 (0.56 to 1.48)             |     | .000    |
| 4 weeks                         | 2.09 (1.84)                | 2.26 (2.59)            | 1.09 (0.050 to 1.68)            |     | .000    |
| 5 weeks                         | 2.17 (1.89)                | 2.38 (2.59)            | 1.19 (0.46 to 1.91)             |     | .001    |
| 6 weeks                         | 2.26 (1.95)                | 2.30 (2.37)            | 1.11 (0.50 to 1.72)             |     | .000    |

(Continues)
| Variables                  | Intervention group (N = 34) | Control group (N = 30) | Regression coefficients (95% CI) | \( B \)  | \( p \)-value |
|---------------------------|----------------------------|------------------------|---------------------------------|--------|-------------|
|                           | 7 weeks (2.23 (2.08)       | 2.17 (2.34)            | 0.95 (0.34 to 1.56)             | .002   |
|                           | 8 weeks (2.00 (1.96)       | 1.82 (2.15)            | 0.68 (−0.01 to 1.38)            | .054   |
|                           | 9 weeks (1.72 (1.91)       | 1.38 (2.03)            | 0.43 (−0.32 to 1.18)            | .259   |
|                           | 10 weeks (1.67 (1.57)      | 1.20 (1.86)            | 0.29 (−0.36 to 0.94)            | .386   |

Pain interference Q3 (0–10) (M, SD)

Overall effect: \( p = 0.58 \)

|                           | 1 week (baseline)         | 2 weeks (1.03 (1.21))   | 1.40 (2.14)                     | .014   |
|                           | 2 weeks (1.23 (1.39))     | 1.43 (2.14)             | 0.44 (0.90 to 0.80)             | .000   |
|                           | 3 weeks (1.81 (1.65)      | 2.11 (2.37)             | 1.12 (0.59 to 1.66)             | .000   |
|                           | 4 weeks (1.86 (1.67)      | 2.36 (2.70)             | 1.50 (0.75 to 2.24)             | .000   |
|                           | 5 weeks (2.10 (1.91)      | 2.38 (2.59)             | 1.50 (0.75 to 2.26)             | .000   |
|                           | 6 weeks (2.23 (1.93)      | 2.07 (2.27)             | 1.24 (0.59 to 1.88)             | .000   |
|                           | 7 weeks (2.16 (2.21)      | 2.03 (2.24)             | 1.18 (0.60 to 1.77)             | .000   |
|                           | 8 weeks (1.74 (1.79)      | 1.77 (2.37)             | 0.95 (0.21 to 1.69)             | .012   |
|                           | 9 weeks (1.55 (1.64)      | 1.42 (2.12)             | 0.87 (0.03 to 1.71)             | .043   |
|                           | 10 weeks (1.54 (1.52)     | 1.16 (1.83)             | 0.74 (−0.02 to 1.49)            | .056   |

Pain interference Q4 (0–10) (M, SD)

Overall effect: \( p = 0.25 \)

|                           | 1 week (baseline)         | 2 weeks (1.70 (2.09))   | 2.08 (2.28)                     | .003   |
|                           | 2 weeks (1.84 (1.96)      | 1.88 (2.28)             | 0.71 (0.24 to 1.18)             | .000   |
|                           | 3 weeks (2.00 (1.97)      | 2.18 (2.47)             | 1.01 (0.47 to 1.55)             | .000   |
|                           | 4 weeks (1.92 (2.00)      | 2.19 (2.66)             | 1.07 (0.52 to 1.62)             | .000   |
|                           | 5 weeks (1.72 (1.86)      | 2.44 (2.62)             | 1.31 (0.68 to 1.94)             | .000   |
|                           | 6 weeks (1.46 (1.59)      | 2.49 (2.68)             | 1.44 (0.81 to 2.06)             | .000   |
|                           | 7 weeks (1.46 (1.56)      | 2.01 (2.24)             | 0.81 (0.36 to 1.26)             | .000   |
|                           | 8 weeks (1.08 (1.19)      | 1.70 (2.05)             | 0.81 (0.23 to 1.40)             | .007   |
|                           | 9 weeks (1.12 (1.23)      | 1.55 (2.24)             | 0.84 (0.12 to 1.55)             | .012   |
|                           | 10 weeks (1.07 (1.29)     | 1.22 (1.10)             | 0.69 (−0.08 to 1.46)            | .078   |

Pain interference Q5 (0–10) (M, SD)

Overall effect: \( p = 0.52 \)

|                           | 1 week (baseline)         | 2 weeks (1.30 (1.72))   | 1.24 (1.96)                     | .019   |
|                           | 2 weeks (1.39 (1.79)      | 1.64 (2.36)             | 0.40 (0.07 to 0.73)             | .001   |
|                           | 3 weeks (1.72 (1.93)      | 2.17 (2.62)             | 0.92 (0.46 to 1.39)             | .000   |
|                           | 4 weeks (1.78 (1.95)      | 2.04 (2.53)             | 0.95 (0.40 to 1.51)             | .001   |
|                           | 5 weeks (1.87 (2.00)      | 2.31 (2.67)             | 1.20 (0.43 to 1.97)             | .002   |
|                           | 6 weeks (1.85 (1.83)      | 1.92 (2.41)             | 0.85 (0.27 to 1.44)             | .004   |
|                           | 7 weeks (1.93 (2.06)      | 1.73 (2.15)             | 0.60 (0.09 to 1.11)             | .022   |
|                           | 8 weeks (1.74 (1.81)      | 1.60 (2.19)             | 0.62 (−0.09 to 1.33)            | .087   |
|                           | 9 weeks (1.51 (1.83)      | 1.36 (1.03)             | 0.50 (−0.19 to 1.19)            | .158   |
|                           | 10 weeks (1.36 (1.51)     | 1.16 (1.72)             | 0.49 (−0.14 to 1.12)            | .128   |

Note: Values presented are model estimates of generalized estimating equations models with a random intercept and adjusted for baseline. Regression coefficients can be interpreted as the time effect for the groups at a certain follow-up moment compared with baseline. Significant differences are bold. The estimated impact (i.e. overall effect) of treatment reflects the “combined” within- and between-subjects effects and Q = question. Pain intensity: Q1 = with speaking, talking and drinking, Q2 = without speaking, talking and drinking. Pain interference: Q1 = general activities, Q2 = mood, Q3 = relations, Q4 = sleep, Q5 = enjoyment of life.

Abbreviations: M, mean; SD, standard deviation.
and seven to depression and is rated on a four-point scale ranging from 0–3. The scores were summed, and the range for each subscale is 0–21. Higher scores indicate likelihood of anxiety or depressive symptoms. A score of 7 or less indicates a non-case, a score of 8–10 a doubtful case and a score of 11 or more a definite case. HADS, a valid and reliable instrument (Bjelland et al., 2002; Zigmond & Snaith, 1983), is widely used in clinical practice, pain care and research and detects anxiety and depressive symptoms in a general setting.

Pain catastrophizing
The Pain Catastrophizing Scale (PCS) measures thoughts or feelings of catastrophizing in relation to how individuals experience pain (Sullivan, Bishop, & Pivik, 1995). The questionnaire comprises 13 items, including subscales for rumination, magnification and helplessness. Each item is scored on a five-point scale from 0 (not at all)–4 (all the time). In this study, the total score was used and summed, and mean values of the items were calculated. The score range is 0–52, with higher scores indicating a worse situation. The PCS, a valid and reliable instrument (Osman et al., 2000), is used in clinical settings and research.

Barriers towards pain
The Barriers Questionnaire II (BQ-II) comprises 27 items on patient-reported beliefs on pain and pain management (Gunnarsdottir et al., 2002; Ward et al., 1993). Each item is measured on a six-point scale – 0 (do not agree at all)–5 (agree very much) – with a total score of 0–135 with higher scores indicating higher barriers. Before this study, BQ-II was translated into Swedish using a backward-forward procedure (Appendix S1, text 1). Cronbach’s alpha coefficient was .90. The BQ-II has been found to have good validity for patient-related barriers to pain management in several studies involving patients with cancer (Gunnarsdottir et al., 2002; Valeberg et al., 2009; Ward et al., 1993).

Current sleep pattern
The Insomnia Severity Index (ISI), a self-reported questionnaire, measures insomnia and provides a measure of the severity of sleep disorders (Bastien, Vallieres, & Morin, 2001). The ISI comprises seven items, and each item is rated on a scale from 0–4, and the total score ranges from 0–28. A higher score suggests more severe insomnia. In this study, one issue about sleep from the ISI was added at the end of the BQ-II and reads as follows: How satisfied are you with your current sleep? The ISI has been found to be a valid and reliable instrument (Savard, Savard, Simard, & Ivers, 2005) and was used because sleep disorders are common in patients with pain.

2.5 Sample size and randomization
The sample size was assessed based on pain intensity (0–10 scale). With an assumed clinically relevant average difference in four scale steps (SD 3), an alpha value of .05 and a power of 80%, each group was calculated to include approximately 30 patients. Every second patient of eligible patients was assigned to the control group (30 patients), and every second patient was assigned to the intervention group (34 patients).

2.6 Allocation concealment mechanism
When patients agreed to participate in the study, their personal data were documented in consecutive order on a list in a confidential data

FIGURE 1 CONSORT flow chart of the recruitment process
1 All patients were assigned a code number and were consecutively distributed to the intervention group or to the control group – every other patient to the control group and every other to the intervention group.

2.7 Statistical methods

All the data were analyzed using SPSS 23.0 for Windows (IBM Corp.). All tests were two-tailed, and statistical significance was defined as a value of \( p \leq 0.05 \). The data are presented as median or mean values with standard deviation (SD) or minimum and maximum values and as percentages (%). The differences between groups at baseline were tested by the Student t tests for continuous variables and chi-square test for dichotomous variables. For the primary outcomes, first the average score was calculated for three time points every week to measure the primary outcomes for 10 weeks. Then, a linear-repeated-measures multilevel model (generalized estimating equations [GEE] continuous variables) was used to determine the effectiveness of the intervention compared with control conditions over time. The estimated impact (i.e. overall effect; Table 4) of treatment on the outcome in the GEE model reflects the "combined" within- and between-subjects effects. The results are presented as regression coefficients (B) with 95% confidence intervals (CI) and can be interpreted as the time effect for the groups at a certain follow-up compared with baseline. In multilevel analysis, missing scores do not need an imputation strategy, as this analysis is flexible in handling missing data. A repeated-measures ANOVA/mixed model (continuous variables) with Bonferroni post hoc tests was used for the secondary outcomes.

3 RESULTS

A total of 119 patients were eligible, and 64 were selected (i.e., randomized) (Figure 1). The patients were randomly assigned to either the control group (30 patients) or the intervention group (34 patients). All 64 patients were analyzed on an intention-to-treat basis. Excluded patients (N = 55) did not meet the inclusion criteria (N = 16) or declined to participate (N = 39). The process of inclusion was ongoing between January 2015–December 2016.

The 64 patients were diagnosed with HNC and informed on the curative intent of RT about 6.0 weeks (median) (min 2–max 711) before inclusion in the study.

The patients completed the first survey questionnaire in mean 7.4 days (SD 5.9 days) after the start of RT. Mean age of the participants was 65.1 years (SD 10.5 years), and the mean age of the non-participants was 70.3 years (SD 12.8 years). Among the participants, 39 (60.9%) were men; the corresponding figure for the non-participants was 31 (66.0%). The only reason reported for denying participating was poor health. Most participants cohabitated (42; 65.6%), most were former smokers (28; 43.8%), 10 (15.6%) were current smokers, and 26 (40.6%) had a university degree (Table 3). We previously have presented descriptive (and BL) data from most participants elsewhere (Schaller et al., 2017). Of the 34 patients, 33 (97.0%) in the intervention group completed the interventions. The reason for withdrawal was poor health.

3.1 Primary outcomes

We evaluated the effects of the intervention with education and SC on pain intensity and pain interference based on the SMS answers by performing repeated-measures GEE model (Table 4; Figures 2 and 3). Missing values were 2%–3% from week 7 to week 10 with respect to all primary outcomes. The results showed no overall significant differences between the control and intervention groups over time.

Figure 2 Scores of primary pain intensity outcomes by short message services (SMS) answers and standard deviation (vertical bars), for the intervention group (N = 34) and the control group (N = 30). Q1 = with speaking, talking and drinking, Q2 = without speaking, talking and drinking. Page 27, Figure 3, above the figure: Q1 = general activities, Q2 = mood, Q3 = relations, Q4 = sleep, Q5 = enjoyment of life.
As expected, time was associated with the primary outcomes (Table 4) in both groups. Compared with BL pain intensity, pain interference on mood and enjoyment of life were higher for weeks 2–7, pain interference on general activities was higher for weeks 3–7, and pain interference on relations with other people and on sleep was higher weeks 2–9. Student’s t tests showed results identical to the GEE analyses.

3.2 | Secondary outcomes

The effects of intervention with education and SC on the secondary outcomes were examined using mixed repeated-measures ANOVA (Table 5; Figures 4 and 5). The between-subjects factor consisted of the two groups (intervention and control), and the within-subjects factor was three time points (BL, 4 and 10 weeks).

No statistically significant differences existed between the two groups except for higher EQ-VAS at BL (Table 5) and sleep satisfaction at 10 weeks (Figure 4) in the intervention group.

For both groups, time was associated with the secondary outcomes (Table 5). Pain intensity and interference were significantly lower at BL compared with 4 and 10 weeks compared with BL. Student’s t tests showed results identical to the mixed repeated-measures ANOVA analyses.

4 | DISCUSSION

This study did not find any significant group differences for the primary outcomes or for the secondary outcomes during RT. The only exception was sleep satisfaction, which was significantly higher in the intervention group at the end of RT. Although the QoL BL scores were significantly higher in the intervention group at BL, they were decreased to the similar level as the control group at the weeks 4 and 10. As expected for both groups, associations with time regarding all outcomes during the RT were found. To our knowledge, no study on pain education and SC for patients with HNC during RT has been published.

Our results are partly in line with previous RCTs on tailored pain education and SC during treatment including, for example, RT for patients with various cancer diseases that did not find any differences in pain intensity (Kravitz et al., 2011). The authors of a review on education and SC (Koller et al., 2012) conclude no improvements for outpatients, a finding that agrees with our study comprised entirely of outpatients. One review concluded, however, that patients with cancer reduced their pain after education and SC (Bennett et al., 2016).
| Variables                          | Baseline mean (SD) | p-value (between groups) | 4 weeks, mean (SD) | p-value (between groups) | 10 weeks, mean (SD) | p-value (between groups) | p-value (within-subjects effect over time) | Significant post hoc comparisons |
|-----------------------------------|--------------------|--------------------------|--------------------|--------------------------|---------------------|--------------------------|---------------------------------------------|----------------------------------|
|                                    | Intervention group | Control group            | Intervention group | Control group            | Intervention group  | Control group            |                                |                                  |
| EQ-5D-index (range −1 to +1)      | Intervention group | Control group            | Intervention group | Control group            | Intervention group  | Control group            |                                |                                  |
| EQ-VAS (range 0–100)              | 80.74 (14.24)      | 68.90 (22.34)            | 68.28 (19.94)      | 61.88 (21.22)            | 74.83 (17.92)       | 72.43 (22.41)            | .67                           | BL versus 4 weeks: p = .000         |
| BPI-intensity (range 0–50)        | 6.85 (7.94)        | 8.13 (9.48)              | 13.0 (8.12)        | 14.27 (11.56)            | 8.28 (8.63)         | 8.46 (10.23)             | .94                           | 4 weeks versus BL: p = .000         |
| BPI-interference (range 0–70)     | 8.26 (9.57)        | 8.46 (11.18)             | 14.82 (11.75)      | 15.96 (17.02)            | 9.53 (10.85)        | 12.67 (15.83)            | .41                           | 4 weeks versus BL: p = .002         |
| HAD-anxiety (range 0–21)          | 3.79 (3.29)        | 3.63 (3.86)              | 2.97 (2.88)        | 3.19 (3.85)              | 2.90 (3.23)         | 2.88 (3.66)              | .98                           | 4 weeks versus BL: p = .037         |
| HAD depression (range 0–21)       | 2.38 (2.34)        | 3.67 (3.74)              | 3.42 (2.90)        | 4.28 (3.76)              | 3.55 (3.41)         | 3.72 (3.34)              | .85                           | BL versus 4 weeks: p = .007         |
| PCS (range 0–52)                  | 8.82 (9.33)        | 9.34 (10.38)             | 7.70 (7.76)        | 9.88 (12.53)             | 9.65 (9.37)         | 7.20 (9.42)              | .34                           | NA                               |
| Sleep pattern (range 0–4)         | 2.21 (1.57)        | 2.15 (1.56)              | 1.42 (1.39)        | 1.20 (1.44)              | 1.00 (1.37)         | 2.08 (1.77)              | .02                           | BL versus 4 weeks: p = .002         |
| BQ-II (range 0–135)               | 54.67 (20.45)      | 48.10 (20.99)            | 39.33 (20.78)      | 38.50 (24.47)            | 38.38 (21.49)       | 38.26 (28.53)            | .99                           | BL versus 4 weeks: p = .000         |

Notes: Significant differences are in bold. The estimated impact (i.e. overall effect) of treatment reflects the "combined" within- and between-subjects effects.
Abbreviations: BL, baseline; BP I, Brief Pain Inventory; BQ-II, Barrier Questionnaire; EQ-5D, EuroQol-5-Dimension Questionnaire; EQ-VAS, Euro Quality of Life Visual Vertical Visual Analogue Scale; HAD, Hospital Anxiety and Depression Scale; NA, not applicable; PCS, Pain Catastrophizing Scale; SD, standard deviation.
FIGURE 4  Scores of secondary outcomes and standard deviation (vertical bars), for the intervention group ($N = 34$) and the control group ($N = 30$).

FIGURE 5  Scores of secondary outcomes with and standard deviation (vertical bars), for the intervention group ($N = 34$) and the control group ($N = 30$).
Bennett et al., 2009; Ling et al., 2012), all patients in our study re-
al., 2009). Consistent with previous research (Babin et al., 2008;

The improvement on sleep satisfaction favouring the intervention
group at week 10 should be treated with caution as the overall results
do not point to significant effects of education and SC, and therefore,
this could represent a random finding. Moreover, sleep satisfaction
was measured using only one item of the ISI despite the fact that this
item was derived from the Swedish version of the ISI, which has good
internal consistency (Dragioti, Wiklund, Alföldi, & Gerdle, 2015). Both
groups had the significantly highest barriers to pain management at
BL. Self-gathering of knowledge (Wong, 2012) and the weekly follow-
ups might have been sources of appropriate information and subse-
quently reduced barriers in both groups. Our results are in line with
a review that concluded that the influence of education on pain man-
agement barriers is limited (Oldenmenger et al., 2009).

One explanation for the mainly similar outcomes of the groups
might be the amount of attention given. That is, SMS, the weekly fol-
low-ups and the survey questionnaire, which included both groups,
might have influenced the relative impact of our interventions.

During the study period, both groups with ongoing cancer treat-
ment in our study necessarily met regularly with other healthcare
professionals – such as oncologists, radiotherapists and dentists –
who provided advice according to their treatment as usual. This es-
cential advice together with the interventions of our project might
have been experienced as excessive information to make efficient
use for the patients and thus might have contributed to a maybe rel-
atively limited impact of our education and SC interventions. In line
with a study of Astrup, Rustøen, Miaskowski, Paul, and Bjordal (2015)
but in contrast to two other studies (Elting, Cooksley, Chambers, &
Garden, 2007; Epstein, Wilkie, Fischer, Kim, & Villines, 2009), the
patients in our study reported relatively low pain intensity. This
might have constituted a floor effect and thus limited effects of our
interventions.

Eight critical core elements of SC education inventions for
patients with cancer have been identified (Howell et al., 2017).
Several of the core elements were closely observed in our study
but some were probably not emphasized enough. Many fac-
tors serve as barriers and facilitators to SC (Riegel, Jaarsma, &
Strömberg, 2012), and our consideration of these factors may
have been insufficient.

We found a tendency, although not significant, to less pain in-
tensity in the intervention group when speaking, eating and talking
and when not performing the above-mentioned activities at approx-
imately the middle of the study period (Figure 2).

The main limitations include the simple method of randomiza-
tion, which may lead to poor allocation concealment and the lack of
blindness, which further accounts for a significant risk of confound-
ing. However, due to the nature of the disease, the blindness in this
study was not possible. The relatively low BL pain intensity may clar-
ify why no significant differences were found (i.e. small possibility of
improvement) and possibly constitutes an unintended bias related
to denial to participate in the study by patients most affected by
the HNC. One may argue that nurses are not trained in teaching pa-
tients, although in our study the intervention was structured, the
TRNs were clinically experienced in the field of pain management
for HNC patients and we can assume that our nursing staff was
highly qualified. The interventions were manualized but treatment
fidelity was not assessed, which might have influenced the accuracy
of the delivered interventions (Dragioti, Dimoliatis, Fountoulakis, &
Evangelou, 2015) beyond their “home-made” nature. Hence, threats
to internal validity may be present.

The strengths of this study include the very low dropout
rates, little missing data and the participants’ recruitment from
the ordinary flow of patients at a department specialized in pain
management at a university hospital. The representativeness of
socio-demographics in our sample was in line with the general
socio-demographic profile of patients with HNC. Thus, we can
infer that our results have population validity. However, ecological
validity and further generalizability also may be limited due to the
relatively less impaired population.

5 | CONCLUSIONS

The study concluded that all included patients felt relatively healthy
during and after RT. The patients generally reported low pain and
good QoL, mood and sleep. However, it was not possible to confirm
that patient education and SC reduced pain intensity or improved
QoL, mood and sleep during and after RT treatment for HNC.

6 | CLINICAL IMPLICATIONS AND FUTURE

The study’s methodology is based on the structure and the con-
tinuity of the personal meeting between the patient and the car-
ergiver and close reporting of symptoms (i.e. pain, QoL, mood and
sleep). This applies to both the control and intervention groups (i.e.
irrespective of patient education). A secondary effect of the study
method probably encouraged the patient to pay attention to per-
ceived symptoms and thus give the caregiver the opportunity to ini-
tiate adequate pain management in time. The study shows that it is
not primarily pain education that the patient needs. Future research
should include the identification of other needs that arise during the
cancer treatment and how to optimize treatment for the patient’s
pain management and QoL.

ACKNOWLEDGEMENTS

We thank Anna Peterson and Marie Berggarden for including pa-
tients in the study and implementing the interventions.
AUTHOR CONTRIBUTIONS

ASS and BL: Study conception and study design. ED, BL ASS and GL: Data analyses and manuscript drafting. All authors discussed the results, commented on the manuscript in different versions and approved the current version of the manuscript.

RESEARCH ETHICS COMMITTEE APPROVAL

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee. (Medical Ethical Board of Linköping University diary number 2014/356-31) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all participants included in the study.

ORCID

Anne Söderlund Schaller https://orcid.org/0000-0002-0380-3365
Elena Dragioti https://orcid.org/0000-0001-9019-4125
Gunilla M. Liedberg https://orcid.org/0000-0003-2980-2835
Britt Larsson https://orcid.org/0000-0001-6924-9910

REFERENCES

Anderson, M. (2019). The Brief Pain Inventory. Retrieved from https://www.mdanderson.org/research/departmentslabs-institutes/departments-divisions/sympptom-research/symptom-assessment-tools/brief-pain-inventory.html
Astrup, G. L., Rustøen, T., Miaskowski, C., Paul, S. M., & Bjordal, K. (2015). Changes in and predictors of pain characteristics in patients with head and neck cancer undergoing radiotherapy. Pain, 156(5), 967–979. https://doi.org/10.1097/J.PAIN.0000000000001422
Babin, E., Sigston, E., Hitler, M., Dehesdin, D., Marie, J. P., & Choussy, O. (2008). Quality of life in head and neck cancers patients: Predictive factors, functional and psychosocial outcome. European Archives of Otorhinolaryngology, 265(3), 265–270. https://doi.org/10.1007/s00405-007-0561-0
Bastien, C. H., Vallieres, A., & Morin, C. M. (2001). Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Medicine, 2(4), 297–307. https://doi.org/10.1016/S1389-9457(00)00665-4
Bennett, M. I., Bagnall, A. M., & Jose Closs, S. (2009). How effective are patient-based educational interventions in the management of cancer pain? Systematic review and meta-analysis. Pain, 143(3), 192–199. https://doi.org/10.1016/j.pain.2009.01.016
Bjelland, I., Dahl, A. A., Haug, T. T., & Neckelmann, D. (2002). The validity of the Hospital Anxiety and Depression Scale. An updated literature review. Journal of Psychosomatic Research, 52(2), 69–77. https://doi.org/10.1016/S0022-3999(01)00296-3
Brooks, R. (1996). EuroQol: The current state of play. Health Policy, 37(1), 53–72. https://doi.org/10.1016/0168-8510(96)00822-6
Cleeland, C. S., & Ryan, K. M. (1994). Pain assessment: Global use of the Brief Pain Inventory. Annals of the Academy of Medicine, Singapore, 23(2), 129–138.
Connelly, S. T., & Schmidt, B. L. (2004). Evaluation of pain in patients with oral squamous cell carcinoma. Journal of Pain, 5(9), 505–510. https://doi.org/10.1016/j.jpain.2004.09.002
Coons, S. J., Rao, S., Keininger, D. L., & Hays, R. D. (2000). A comparative review of generic quality-of-life instruments. Pharmacoeconomics, 17(1), 13–35. https://doi.org/10.2165/00001905-200017100-00002
Denyes, M. J., Orem, D. E., Bekel, G., & SozWiss. (2001). Self-care: A foundational science. Nursing Science Quarterly, 14(1), 48–54. https://doi.org/10.1177/089431840101400113
Dodd, M. J., Cho, M. H., Miaskowski, C., Painter, P. L., Paul, S. M., Cooper, B. A., ... Bank, K. A. (2010). A randomized controlled trial of home-based exercise for cancer-related fatigue in women during and after chemotherapy with or without radiation therapy. Cancer Nursing, 33(4), 245–257. https://doi.org/10.1097/NCC.0b013e3181dcd58c
Dolan, P. (1997). Modeling valuations for EuroQol health states. Medical Care, 35(11), 1095–1108. https://doi.org/10.1097/00005650-199710000-00002
Dragioti, E., Dimilis, I., Fountoulakis, K. N., & Evangelou, E. (2015). A systematic appraisal of allegiance effect in randomized controlled trials of psychotherapy. Annals of General Psychiatry, 14, 25. https://doi.org/10.1186/s12991-015-0063-1
Dragioti, E., Wiklund, T., Alfeldi, P., & Gerdle, B. (2015). The Swedish version of the Insomnia Severity Index: Factor structure analysis and psychometric properties in chronic pain patients. Scandinavian Journal of Pain, 9, 22–27. https://doi.org/10.1016/j.sjpain.2015.06.001
Du, S., Yuan, C., Xiao, X., Chu, J., Qiu, Y., & Qian, H. (2011). Self-management programs for chronic musculoskeletal pain conditions: A systematic review and meta-analysis. Patient Education and Counseling, 85(3), e299–310. https://doi.org/10.1016/j.pec.2011.02.021
Elting, L. S., Cooksley, C. D., Chambers, M. S., & Garden, A. S. (2007). Risk, outcomes and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. International Journal of Radiation Oncology, Biology, Physics, 68(4), 1110–1120. https://doi.org/10.1016/j.ijrobp.2007.01.053
Epstein, J. B., Hong, C., Logan, R. M., Barasch, A., Gordon, S. M., Oberlee-Edwards, L., ... Brennan, M. T. (2010). A systematic review of orofacial pain in patients receiving cancer therapy. Supportive Care in Cancer, 18(8), 1023–1031. https://doi.org/10.1007/s00520-010-0897-7
Epstein, J. B., Wilkie, D. J., Fischer, D. J., Kim, Y. O., & Villines, D. (2009). Neuropathic and nociceptive pain in head and neck cancer patients receiving radiation therapy. Head & Neck Oncology, 1, 26. https://doi.org/10.1186/1758-3284-1-26
Fayers, P. M., & Machin, D. (2013). Quality of life: The assessment, analysis and interpretation of patient-reported outcomes. West Sussex, England: John Wiley & Sons, Ltd.
Gunnarsdottir, S., Donovan, H. S., Serlin, R. C., Voge, C., & Ward, S. (2002). Patient-related barriers to pain management: The Barriers Questionnaire II (BQ-II). Pain, 99(3), 385–396. https://doi.org/10.1016/S0304-3959(02)00243-9
Haisfield-Wolfe, M. E., McGuire, D. B., Soeken, K., Geiger-Brown, J., DeForge, B., & Suntharalingam, M. (2012). Prevalence and correlates of symptoms and uncertainty in illness among head and neck cancer patients receiving definitive radiation with or without chemotherapy. Supportive Care in Cancer, 20(8), 1885–1893. https://doi.org/10.1007/s00520-011-1291-9
Howell, D., Harth, T., Brown, J., Bennett, C., & Boyko, S. (2017). Self-management education interventions for patients with cancer: A systematic review. Supportive Care in Cancer, 25(4), 1323–1355. https://doi.org/10.1007/s00520-016-3500-z
Jho, H. J., Myung, S. K., Chang, Y. J., Kim, D. H., & Ko, D. H. (2013). Efficacy of pain education in cancer patients: A systematic review. Supportive Care in Cancer, 21(7), 1963–1971. https://doi.org/10.1007/s00520-013-1756-0
Johnston, B., McGill, M., Milligan, S., McElroy, D., Foster, C., & Kearney, N. (2009). Self-care and end of life care in advanced cancer: Literature review. European Journal of Oncology Nursing, 13(5), 386–398. https://doi.org/10.1016/j.ejon.2009.04.003
